GenSight Biologics

France
Plumergat, Brittany, France, 75012

Company profile

GenSight Biologics company profile

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Business identity

Contact email
[email protected]
Phone number
+33 1 76 21 72 20
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Postal code
75012
Country code
FR
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
21
Total equity funding
$217.8M
Last funding
Post IPO Equity / $3.4M / 2025-12-26
Last equity funding
Post IPO Equity / $3.4M
Investors
20
Lead investors
10
Founders
5
Articles
156
Exited on
2016-07-13

Founders and investors

Founders

Bernard GillyBotond RoskaJose Alain SahelLuk VandenbergheSerge Picaud

Lead investors

AbingworthArix BioscienceEuropean Investment BankHeights Capital ManagementIndex VenturesInvusKreos CapitalNovartis Venture FundSofinnova PartnersVersant Ventures

Investors

BpifranceEuropean Investment BankFidelityIndex VenturesPerceptive Advisors